Rarebird is a New York and San Leandro-based specialty coffee company that replaces caffeine with paraxanthine (Px), the natural metabolite your body turns caffeine into. Founded by bioengineer Dr. Jeffrey Dietrich, Rarebird uses a patented reverse-infusion process to load 60mg of Px into single-origin Colombian decaf beans, promising alertness and focus without the jitters, anxiety, cortisol spikes, or wrecked sleep. Backed by Y Combinator, AgFunder, First Round Capital and the National Science Foundation, Rarebird is trying to make Px 'the third coffee' - a category alongside regular and decaf.
Jeffrey Dietrich is a bioengineer-turned-coffee-founder who built Rarebird around paraxanthine, the molecule your body actually makes when it metabolizes caffeine. After a PhD at UC Berkeley in Jay Keasling's lab and nearly a decade co-founding and running R&D at the industrial biotech company Lygos, Dietrich turned his own dwindling caffeine tolerance into a company. Rarebird sells decaffeinated specialty coffee infused with lab-grade paraxanthine, promising the lift of coffee without the jitters, crash, or ruined sleep. Backed by Y Combinator, AgFunder, and two NSF grants, the company holds U.S. patents on the process and won the Specialty Coffee Association's Best New Product award.